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INTRODUCTION
Krill are red shrimp-like crustaceans that live in the cold waters of the southern (Antarctic) and northern (Arctic) polar seas. 1 Although krill is the main food source for whales, it remains an abundant biomass on earth because of its high proliferation properties. 2 Krill have a short lifespan (1-2 years) and, because they live in clean waters, are free of heavy metals, pesticides, and dioxins. 2 The major krill species, Euphausia superba, known as Antarctic krill, is the source of extracted krill oil. 3 Many experimental and clinical trials have reported a protective role of krill oil in chronic inflammation, 2 dyslipidemia, 4 premenstrual syndrome, 5 osteosarcoma, 6 and rheumatoid arthritis. 7 Krill oil is rich in phospholipids that contain n-3 polyunsaturated fatty acids, mainly eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA). 8 It also contains various potent antioxidants, such as the carotenoid astaxanthin, and vitamins A and E. 9 The association between phospholipids and long-chain n-3 fatty acids greatly facilitates the passage of fatty acid molecules through the intestinal wall, thereby increasing their bioavailability and improving the ratio of n-3 to n-6 fatty acids. 3, 10 Most of krill oil's benefits have been attributed to its high EPA and DHA content. 11 The well-recognized metabolic effects of EPA and DHA include lowering of triglyceride (TG) and very low-density lipoprotein cholesterol levels. 12 Choline, an ingredient in krill oil, reduces homocysteine, transports different lipids, and is involved in the synthesis of neurotransmitters (acetylcholine) and phospholipids (sphingomyelin, lyso-phosphatidylcholine, phosphatidylcholine, and choline plasmalogen). 13 The lipid-modifying effects of krill oil have been demonstrated in some trials, but the data are still inconclusive. Therefore, all published trials on krill oil supplementation were reviewed systematically and assessed to determine the overall efficacy of krill oil on plasma lipids using meta-analysis.
METHODS

Search strategy
This systematic review and meta-analysis was performed in compliance with the PRISMA guidelines. 14 The Scopus and MEDLINE databases were searched using the following search terms in titles and abstracts (also in combination with MeSH terms): ("randomized controlled trial" OR "randomized" OR "placebo" OR "cholesterol" OR "triglyceride" OR "LDL" OR "LDL-C" OR "LDL-cholesterol" OR "HDL" OR "HDL-C" OR "HDL-cholesterol" OR "hyperlipidemia" OR "hyperlipidemic" OR "hypolipidemic" OR "dyslipidemia" OR "dyslipidemic") and ("krill oil" OR "euphausiaceae" OR "euphausia superba"). The wild-card term ''*'' was used to increase the sensitivity of the search strategy. The literature search was limited to papers published in English and to studies conducted in humans. The literature was searched from inception to March 25, 2016 .
Two investigators (S.U. and M-C.S.) independently assessed each article, carried out data extraction, and performed quality assessment. Disagreements were resolved by consensus and discussion with a third party (M.B.).
The PICOS (Participants, Intervention/exposure, Comparison, Outcomes, Study design) criteria used to define the research question are shown in Table 1 .
Study selection
The following criteria were used for the inclusion of original articles in the meta-analysis: a randomized controlled design; investigation of the effects of krill oil on plasma/ serum concentrations of at least one of the main lipid parameters (ie, total cholesterol, low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), or TGs; measurement of either plasma/serum concentrations of lipids at baseline and at the end of study in both krill oil and control groups or the net change in lipid levels during the study; and administration of krill oil for a period of at least 2 weeks. The following exclusion criteria were applied: experimental studies; uncontrolled trials; administration of krill oil preparations for <2 weeks; and lack of reporting of baseline or follow-up lipid concentrations or the net change in lipid levels during the study.
Data extraction
Studies meeting the inclusion criteria were reviewed, and data regarding authors, study location, publication date, size of study population, trial design, dose and duration of intervention, control group allocation, baseline characteristics of study population (including age, gender, and body mass index), and changes in plasma concentrations of lipids were extracted.
Quality assessment
Risk of bias in the studies considered in this metaanalysis was evaluated according to the Cochrane instructions. 15 Selection bias, performance bias, attrition bias, detection bias, reporting bias, and other sources of bias were judged to be high, low, or unclear in each of the studies included.
Quantitative data synthesis
Comprehensive Meta-Analysis V2 software (Biostat, NJ, USA) 16 was used for statistical procedures. Plasma concentrations of lipids and lipoproteins were collated in milligram per deciliter. Inverse variance-weighted mean differences (WMDs) and 95% confidence limits were used as the summary statistics and calculated as previously described, 17, 18 considering a correlation coefficient of 0.5. When standard deviation values were not reported in a study, they were imputed by the pooled standard deviations from other studies. Meta-analysis was performed under fixed-and random-effects models when I 2 (heterogeneity) values were <50% and !50%, respectively. For trials with more than one treatment arm and a single control group, the number of subjects in the control group was divided into a corresponding number of smaller groups. In order to evaluate the influence of each study on the overall effect size, sensitivity analysis was conducted using the one-study remove (leave-one-out) approach. Leave-one-out sensitivity analysis is a simple method to check if the overall estimate of effect is significantly driven by a single study or treatment arm. In this method, all included treatment arms are iteratively removed from the analysis, the effect size is calculated, and the significance of the pooled estimate is evaluated. 19 
Meta-regression
As potential confounders of treatment response, dosage and duration of supplementation with krill oil were entered into a meta-regression model to explore their association with the estimated effect size in each lipid species.
Publication bias
Funnel plot evaluation, Begg's rank correlation, and Egger's weighted regression tests were employed to assess the presence of publication bias in the metaanalysis. When there was evidence of funnel plot asymmetry, potentially missing studies were imputed using the trim-and-fill method. In the case of a significant result, the number of potentially missing studies required to make the P value nonsignificant was estimated using the fail-safe N method as another marker of publication bias.
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RESULTS
Search results and trial flow
The initial screening for potential relevance removed the articles whose titles and/or abstracts were obviously irrelevant. Of the 15 full-text articles assessed for eligibility, 8 were excluded for the following reasons: did not measure plasma lipid levels (n ¼ 4), investigated bioavailability of fatty acids only (n ¼ 1), and did not have an appropriate randomized controlled trial [RCT] design) (n ¼ 3) (Figure 1 ). After assessment, 7 RCTs (equivalent to 14 treatment arms) met the inclusion criteria and were used for the final meta-analysis. In total, 427 participants were allocated to a krill oil supplementation group and 235 to a control group in the selected studies. 4, [24] [25] [26] [27] [28] [29] The number of participants in these trials ranged from 20 to 267. Included studies were published between 2004 and 2015 and were conducted in Canada (n ¼ 3), Norway (n ¼ 2), and the United States (n ¼ 2). All studies used 500-mg capsules or softgels of krill oil, and the dosages ranged from 500 mg/d to 4 g/d. Duration of supplementation with krill oil ranged between 4 weeks and Randomized controlled trials with a parallel or crossover design 3 months. Four trials were designed as parallel-group studies and 3 had a crossover design. Three studies were multicenter. Demographic and baseline parameters of the included studies are shown in Table 2 .
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The common side effects usually observed after administration of fish oil supplements, such as reflux, fishy aftertaste, or belching of fish flavors, were not reported after krill oil intake. Except for a few cases of mild to moderate gastrointestinal symptoms, krill oil was safe and well tolerated in all of the RCTs included in this review. No adverse events related to the supplementation were reported.
Risk-of-bias assessment
The risk of bias with respect to sequence generation and allocation concealment was unclear, but studies were of low risk in terms of other sources of bias. The systematic assessment of bias in the included studies is shown in Table 3 .
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Quantitative data synthesis
Total cholesterol. The meta-analysis of RCTs showed a reduction in plasma total cholesterol levels following supplementation with krill oil, but this reduction did not reach statistical significance (WMD, À7.5 mg/dL; 95%CI, À17.94 to 2.93; P ¼ 0.159) ( Figure 2 ). This effect size was robust in the sensitivity analysis ( Figure 3 ). The effect of krill oil on plasma total cholesterol concentrations was not different in subgroups of RCTs with dosages of either <2 g/d or !2 g/d. With respect to treatment duration, there was a significant reduction in total cholesterol concentrations in the subset of RCTs lasting !12 weeks but not in the subset lasting <12 weeks (Table 4) . Visual inspection of the funnel plot as well as the results of Begg's rank correlation and Egger's linear regression tests suggested potential publication bias in the meta-analysis of krill oil's effects on plasma total cholesterol concentrations (Table 5 and Figure 4 ).
Low-density lipoprotein cholesterol. A significant reduction in plasma concentrations of LDL-C was observed following supplementation with krill oil (WMD, À15.52 mg/dL; 95%CI, À28.43 to À2.61; P ¼ 0.018) (Figure 2 ). This effect size was sensitive to one of the included studies 4 ( Figure 3 ). The effect of krill oil on LDL-C concentrations did not reach statistical significance in subgroups of RCTs with dosages of either <2 g/d or !2 g/d. Regarding treatment duration, there was a significant reduction in plasma LDL-C in the subset of RCTs with supplementation durations !12 weeks but not in the subset with supplementation lasting <12 weeks (Table 4) . Visual inspection of the funnel plot as well as the results of Begg's rank correlation and Egger's linear regression tests suggested potential publication bias in the meta-analysis of krill oil's effects on plasma LDL-C concentrations (Table 4 and Figure 4 ).
High-density lipoprotein cholesterol.
The meta-analysis of RCT data suggested a significant elevation in plasma HDL-C concentrations following krill oil supplementation (WMD, 6.65 mg/dL; 95%CI, 2.30-10.99; P ¼ 0.003) (Figure 2 ). This effect size was robust in the sensitivity analysis, and iterative removal of each single study from the meta-analysis did not affect the statistical significance of the effect size (Figure 3 ). In the subgroup analysis, there was a significant increase in plasma HDL-C concentrations in the subset of trials with krill oil dosages of !2 g/d but not in the subset with dosages of <2 g/d. With respect to the duration of supplementation, HDL-C elevations remained significant in both study subsets with supplementation durations of <12 weeks and !12 weeks, though a greater reduction was observed in the latter subgroup (Table 4) .
Visual inspection of the funnel plot as well as the results of Begg's rank correlation and Egger's linear regression tests suggested potential publication bias in the meta-analysis of krill oil's effects on plasma HDL-C concentrations (Table 5 and Figure 4 ).
Triglycerides. A significant reduction in plasma TG concentrations following krill oil supplementation was found in the meta-analysis of RCTs (WMD, À14.03 mg/dL; 95%CI, À21.38 to À6.67; P < 0.001) (Figure 2 ). This effect size was robust in the sensitivity analysis, and iterative removal of each single study from the meta-analysis did not affect the statistical significance of the effect size (Figure 3 ). In the subgroup analysis, there was a significant reduction in plasma TG concentrations in both subsets of trials with krill oil doses of <2 g/d and !2 g/d. However, with respect to supplementation duration, significant reduction of plasma TG concentrations was observed only in the subset of RCTs lasting !12 weeks and not in the subset lasting <12 weeks (Table 4) . Although the results of Begg's rank correlation and Egger's linear regression tests did not indicate any publication bias (Table 5 ), the funnel plot was slightly asymmetric, suggesting potential publication bias in the meta-analysis of krill oil's effects on plasma TG concentrations. Using Duval and Tweedie trim-and-fill correction, 3 potentially missing studies were imputed on the left side of funnel plot, yielding a corrected effect size of À15.12 mg/dL (95%CI, À22.00 to À8.23) (Figure 4) .
DISCUSSION
To the best of knowledge, the current systematic review and meta-analysis is the first to analyze evidence from RCTs on the effect of krill oil supplementation on plasma lipids. The results showed a significant reduction in plasma concentrations of LDL-C and TGs and a significant elevation in plasma HDL-C concentrations following supplementation with krill oil, while a reduction in plasma total cholesterol levels did not reach statistical significance. When the studies were stratified according to their duration, there was a significant reduction in total cholesterol, LDL-C, and TGs in the subset of RCTs lasting !12 weeks but not in the subset lasting <12 weeks, while HDL-C elevations remained significant in both study subsets.
The favorable effects of krill oil on the lipid profile found in the current meta-analysis suggest the use of this marine product as an interesting add-on therapy in dyslipidemic patients. However, the exact mechanisms responsible for the lipid-lowering effects of krill oil are not completely understood. It has been shown that krill oil acts more as an antihyperlipidemic product than a hypolipidemic one, since TGs and cholesterol levels are lowered in patients with elevated blood lipids, but not in healthy volunteers. 26 It has been proved that krill oil reduces the expression of genes required for lipid and isoprenoid/cholesterol synthesis. 30 In contrast, fish oil modulates expression of several genes, such as peroxisome proliferator-activated receptor (PPAR)-a, sterol regulatory element-binding proteins (SREBP)-1, and 29 
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Unclear Low Low Low Low Low Figure 2 Forest plots detailing weighted mean differences and 95% confidence intervals for the effect of krill oil supplementation on plasma lipid concentrations. Abbreviations: HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; TC, total cholesterol; TG, triglycerides. Figure 3 Leave-one-out sensitivity analysis for the effects of krill oil supplementation on plasma lipid concentrations. Abbreviations: HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; TC, total cholesterol; TG, triglycerides. 
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Abbreviations: LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol; WMD, weighted mean difference. Figure 4 Funnel plots detailing publication bias in the studies selected for analysis. Trim-and-fill method was used to impute for potentially missing studies. Open circles represent observed published studies; closed circles represent imputed unpublished studies. Abbreviations: HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; TC, total cholesterol; TG, triglycerides.
(SREBP)-2, all involved in triacylglycerol and fatty acid catabolism in skeletal muscle and liver. 31 A higher bioavailability of long-chain n-3 polyunsaturated fatty acids and a higher therapeutic effect 1 has been observed in studies comparing the efficacy of krill oil with that of fish oil. 5, 26, 27, 32 The association between long-chain n-3 fatty acids and phospholipids is responsible for lipogenic effects of krill oil, while the association between n-3 fatty acids and TGs is culpable for the lipogenic effects of fish oil. 3 Phospholipids are amphipathic molecules that do not require emulsification via bile salts like the hydrophobic TGs, hence they are able to move easily across the intestinal wall and cell membranes. 5 Therefore, the association between longchain n-3 fatty acids and phospholipids might have an important role in improving the bioavailability and absorption of fatty acids through the intestinal wall and enhancing the n-3:n-6 ratio. 27 The different effects of krill oil as compared with fish oil on lipid parameters in experimental studies might be also explained by the different effects of these oils on the secretion of very lowdensity lipoprotein and the distinct modulation of gene expression in the intestine and the liver. 33 Moreover, experimental studies showed that krill oil is capable of upregulating the activity of the mitochondrial respiratory chain and downregulating the activity of pathways involved in lipid and cholesterol synthesis and hepatic glucose production, while fish oil did not modulate the same metabolic pathways regulated by krill oil. 30 While fish oil upregulates the cholesterol synthesis pathway, the effect of krill oil is the opposite. 30 An experimental study in rats fed a krill-oil-enriched diet has shown that krill oil might have the capacity to inhibit de novo lipogenesis by decreasing the activity of both cytosolic acetyl coenzyme A carboxylase and the mitochondrial citrate carrier and to increase the oxidation of fatty acids by decreasing the fatty acid synthetase activity. 34, 35 Another unique feature of krill oil is related to its powerful antioxidant astaxanthin, which has a slight, but not significant, glucose-lowering effect on plasma lipid concentrations. 36 Another important antioxidant found in krill oil is vitamin E, known for its capacity to protect biological membranes against lipid peroxidation. 37 Nevertheless, krill oil is a rich source of high-quality protein in the range of 60% to 65% dry weight, including all 9 essential amino acids required by adults. 38 One study showed that daily consumption of 3 g of krill oil formulated with 543 mg of EPA and DHA raises the plasma EPA and DHA concentrations exactly the same as intake of fish oil containing 864 mg of EPA and DHA. 27 Another new study in healthy subjects showed that the proportion of EPA and DHA in plasma phospholipid fatty acids measured during a 72-hour follow-up as an incremental area under the curve was significantly larger after krill oil ingestion than after fish oil ingestion. 9 The adverse effects observed after krill oil consumption are observed only in individuals with known allergies to different crustaceans or shellfish, such as shrimp or crabs. 1, 39 Moreover, patients who take krill oil and anticoagulant/antiplatelet drugs simultaneously might have an increased risk of bleeding.
The present meta-analysis has some limitations. Most of the included studies had a small number of participants and were heterogeneous with regard to the characteristics of patients. Moreover, the lipid profile and content of krill oil could fluctuate appreciably according to conditions such as the krill species used, the age of the krill, the season harvested, and the delay time between collection and freezing. The effects of krill on small, dense LDL subfractions and HDL function do not seem to have been investigated. The function of HDL may be even more relevant than its measured levels. 13 However, the effect of krill oil on TG and HDL-C levels suggests there will be an improvement in small, dense LDL subfractions. 40 The baseline dietary data and the prescribed diet were not clearly described in all the studies included. In this meta-analysis, the most significant effects on plasma lipids were reported in the treatment arms in the study by Bunea et al. 4 Although the impact of each treatment arm on the overall estimated effect size was explored in the sensitivity analysis, another attempt was made to assess the impact of this study on the effect size by removing all treatment arms in this study from the meta-analysis. The results revealed that, although the TG-lowering effect of krill oil remains significant, the effects on LDL-C and Number of studies (calculated using the fail-safe N method) required to make the P value nonsignificant.
HDL-C were no longer evident when the study of Bunea et al. 4 was excluded. This highlights the need for future studies to better evaluate whether krill oil supplementation exerts a LDL-lowering effect. Finally, the value of adding krill oil to conventional and novel lipid-lowering medications [41] [42] [43] [44] remains unknown.
CONCLUSION
The present meta-analysis of RCTs suggests the efficacy of krill oil supplementation in lowering plasma concentrations of LDL-C and TGs as well as increasing those of HDL-C. Further, well-designed clinical studies with higher numbers of participants are necessary to assess the impact of krill oil supplementation on other indices of cardiometabolic risk and on the risk of cardiovascular outcomes. The value of adding krill oil to statins and other routinely administered lipid-lowering therapies is also open to question.
